We Give Shareholders a Voice

Tetraphase Pharmaceuticals, Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Tetraphase Pharmaceuticals, Inc. (“Tetraphase” or the “Company”) (NASDAQ: TTPH) to AcelRx Pharmaceuticals, Inc. (“AcelRx”) (NASDAQ: ACRX). Under the terms of the merger, Tetraphase stockholders will receive, for each share of Tetraphase common stock, 0.6303 of a share of AcelRx common stock and one contingent value right.

The Tetraphase merger investigation concerns whether the Board of Tetraphase breached their fiduciary duties to stockholders by agreeing to enter into this transaction and whether the merger undervalues Tetraphase relative to AcelRx, thereby harming Tetraphase shareholders.

To receive more information, please fill out the form.

Enter Your Details Below

This submission does not create an attorney-client relationship. We will keep you up to date with this investigation, and should this investigation evolve, we will contact you to discuss whether to establish an attorney client relationship at no cost to you.

Review our Privacy Policy